|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/11/20 Rubius Therapeutics, Inc. 10-Q 3/31/20 53:5M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 983K
2: EX-10.1 Material Contract HTML 118K
3: EX-10.2 Material Contract HTML 119K
4: EX-31.1 Certification -- §302 - SOA'02 HTML 25K
5: EX-31.2 Certification -- §302 - SOA'02 HTML 24K
6: EX-32.1 Certification -- §906 - SOA'02 HTML 20K
7: EX-32.2 Certification -- §906 - SOA'02 HTML 20K
47: R1 Document and Entity Information HTML 48K
28: R2 Condensed Consolidated Balance Sheets HTML 94K
18: R3 Condensed Consolidated Balance Sheets HTML 37K
(Parenthetical)
36: R4 Condensed Consolidated Statements of Operations HTML 63K
and Comprehensive Loss
48: R5 Condensed Consolidated Statements of Operations HTML 20K
and Comprehensive Loss (Parenthetical)
29: R6 Condensed Consolidated Statements of Cash Flows HTML 92K
19: R7 Condensed Consolidated Statements of Stockholders? HTML 51K
Equity (Deficit)
38: R8 Nature of the Business and Basis of Presentation HTML 29K
45: R9 Summary of Significant Accounting Policies HTML 58K
41: R10 Investments and Fair Value of Financial Assets and HTML 161K
Liabilities
49: R11 Property, Plant and Equipment, Net HTML 54K
26: R12 Accrued Expenses and Other Current Liabilities HTML 40K
14: R13 Debt HTML 34K
42: R14 Equity HTML 24K
50: R15 Stock-Based Compensation HTML 34K
27: R16 Commitments and Contingencies HTML 27K
15: R17 Net Loss Per Share HTML 53K
40: R18 Summary of Significant Accounting Policies HTML 76K
(Policies)
51: R19 Investments and Fair Value of Financial Assets and HTML 162K
Liabilities (Tables)
23: R20 Property, Plant and Equipment, Net (Tables) HTML 52K
21: R21 Accrued Expenses and Other Current Liabilities HTML 40K
(Tables)
34: R22 Debt (Tables) HTML 30K
52: R23 Stock-Based Compensation (Tables) HTML 32K
24: R24 Net Loss Per Share (Tables) HTML 56K
22: R25 Nature of the Business and Basis of Presentation HTML 44K
(Details)
35: R26 Summary of Significant Accounting Policies HTML 33K
(Details)
53: R27 Investments and Fair Value of Financial Assets and HTML 89K
Liabilities (Details)
25: R28 Property, Plant and Equipment, Net (Details) HTML 53K
20: R29 Accrued Expenses and Other Current Liabilities HTML 31K
(Details)
17: R30 Debt (Details) HTML 57K
32: R31 Equity (Details) HTML 53K
46: R32 Stock-Based Compensation - Performance based stock HTML 26K
options (Details)
39: R33 Stock-Based Compensation - Compensation expense HTML 31K
(Details)
16: R34 Commitments and Contingencies - Collaborative HTML 25K
Arrangements and Non-collaborative Arrangement
(Details)
30: R35 Commitments and Contingencies - Defined HTML 25K
Contribution Plan (Details)
44: R36 Net Loss Per Share - Weighted Average Shares HTML 29K
(Details)
37: R37 Net Loss Per Share - Antidilutive Securities HTML 30K
(Details)
33: XML IDEA XML File -- Filing Summary XML 87K
31: EXCEL IDEA Workbook of Financial Reports XLSX 52K
8: EX-101.INS XBRL Instance -- ruby-20200331 XML 989K
10: EX-101.CAL XBRL Calculations -- ruby-20200331_cal XML 103K
11: EX-101.DEF XBRL Definitions -- ruby-20200331_def XML 243K
12: EX-101.LAB XBRL Labels -- ruby-20200331_lab XML 760K
13: EX-101.PRE XBRL Presentations -- ruby-20200331_pre XML 485K
9: EX-101.SCH XBRL Schema -- ruby-20200331 XSD 91K
43: ZIP XBRL Zipped Folder -- 0001558370-20-006124-xbrl Zip 92K
| ruby_Ex31_2 |
CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
CERTIFICATIONS
I, Andrew M. Oh, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Rubius Therapeutics, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)):
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
Date: May 11, 2020 |
|
By: |
/s/ Andrew M. Oh |
|
|
|
|
|
|
|
|
|
Chief Financial Officer |
|
|
|
|
(Principal Financial Officer) |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 5/11/20 | 8-K | ||
| For Period end: | 3/31/20 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/25/22 Rubius Therapeutics, Inc. 10-K 12/31/21 74:10M Toppan Merrill Bridge/FA 3/18/21 Rubius Therapeutics, Inc. 424B5 1:772K Toppan Merrill/FA 3/15/21 Rubius Therapeutics, Inc. 424B5 1:774K Toppan Merrill/FA 2/23/21 Rubius Therapeutics, Inc. 10-K 12/31/20 82:12M Toppan Merrill Bridge/FA |